When Pharma Meets the Courtroom: Why Neutral Third-Party Material Management Matters in Litigation

In pharmaceutical legal disputes — especially patent litigation, product liability cases, and regulatory investigations — the science isn’t the only thing that matters. The integrity of the material itself can determine the integrity of the case.

Whether the disputed item is an API, finished drug product (DP), or biologic, legal teams often face a non-scientific but mission-critical challenge:

Who will receive, store, monitor, document, and distribute the material in a way that both sides — and the court — can trust?

The answer increasingly lies with a specialized CRO that can operate as a neutral third-party custodian, managing pharmaceutical materials under GxP-grade controls similar to clinical supply chain discipline, but adapted for evidence-grade admissibility.

What Makes Material Handling “Court-Defensible”?

To support legal admissibility, a material management partner must provide:

Neutral third-party handling

• Inventory stored in restricted-access areas
• Role-based access control
• Optional dual-control custody cages when required by protective order

Formal Chain-of-Custody (CoC)

• Every touchpoint logged
• Barcode tracking
• Tamper-evident seals

Optional witness attestations and affidavits

• Validated Temperature Storage
• CRT / Ambient (15–25°C)
• 2–8°C refrigerated
• -20°C and -80°C frozen
• Cryogenic/LN2 storage for CGT and critical biologics
• Includes calibrated sensors, temperature mapping, 24/7 monitoring, alarms, and documented excursion investigations

Qualified Cold-Chain Logistics

• Validated GxP-grade shipping containers
• Temperature data loggers in all cold shipments
• Retrieval and archival of full temperature traces
• Pre-defined acceptable ranges and excursion disposition rules

 

Receiving, Quarantine & Release Controls

• Documented inspection upon receipt
• Quarantine controls applied where required (especially for API/DP)
• GxP-style release records before distribution

Multi-Party Distribution Support

• Split shipments or aliquots to multiple legal parties
• Packaging configurations archived
• Final CoC closure with return or destruction options

What Types of Material Are Typically Involved?

A litigation-grade material custodian must be able to manage:

• Active Pharmaceutical Ingredients (API)
• Drug Products (DP)
  • Finished, in-process, or retained lots
  • Tablets, solutions, vials, syringes, nasal sprays, etc.
• Biologics
  • Proteins, antibodies, diagnostic reagents, CGT materials, reference standards, internal controls

Why This Matters More Than Ever

Material mishandling can lead to:

• Evidence being ruled inadmissible
• Chain-of-custody gaps that undermine credibility
• Temperature excursions without documented investigations
• Distribution challenges under protective orders
• Lost trust between opposing legal teams

By contrast, a neutral GxP-aligned CRO partner brings:

• Auditable custody integrity
• Validated environmental controls
• Excursion investigation and disposition discipline
• Defensible documentation packages
• Neutrality that both sides can agree on

How Emery Pharma Supports These Legal Requirements

Emery Pharma has adapted its GLP/GMP/GDP infrastructure and quality systems to support:

• Neutral third-party evidence custody
• Formal Chain-of-Custody logging
• Validated temperature storage environments
• Qualified cold-chain logistics
• Quarantine and release control discipline
• Multi-party legal distribution under protective order frameworks
• Custody closure via return or documented destruction

These capabilities allow Emery Pharma to support high-stakes legal and regulatory proceedings involving APIs, drug products, and biologics, ensuring the material is handled with the same rigor expected in clinical supply chain, but with evidence-grade auditability and legal neutrality.

Common Legal Use Cases

• Patent litigation requiring neutral storage + distribution to all counsel-approved parties
• Quality disputes requiring custody integrity + excursion disposition
• Regulatory investigations requiring GxP-style evidence traceability
• Biologics disputes requiring ultra-cold or cryogenic storage with monitoring
• Protective orders requiring dual access controls and witnessed custody events

Final Takeaway

In pharma litigation, success demands both:

• The right science
• The right evidence discipline

Neutral third-party material management bridges the gap.

Emery Pharma — Where Science, Compliance & Neutrality Meet. Delivered with Integrity.

Written by:

Dr. Ron Najafi

Founder & CEO, Emery Pharma (GLP/GMP Analytical & Bioanalytical CRO)